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High expression of QSOX1 reduces
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Abstract
Introduction: The gene quiescin/sulfhydryl oxidase 1, QSOX1, encodes an enzyme directed to the secretory
pathway and excreted into the extracellular space. QSOX1 participates in the folding and stability of proteins and
thus could regulate the biological activity of its substrates in the secretory pathway and/or outside the cell. The
involvement of QSOX1 in oncogenesis has been studied primarily in terms of its differential expression in systemic
studies. QSOX1 is overexpressed in prostate cancers and in pancreatic adenocarcinoma. In contrast, QSOX1 gene
expression is repressed in endothelial tumors. In the present study, we investigated the role of QSOX1 in breast
cancer.
Methods: We analyzed QSOX1 mRNA expression in a cohort of 217 invasive ductal carcinomas of the breast.
Moreover, we investigated QSOX1’s potential role in regulating tumor growth and metastasis using cellular models
in which we overexpressed or extinguished QSOX1 and xenograft experiments.
Results: We showed that the QSOX1 expression level is inversely correlated to the aggressiveness of breast tumors.
Our results show that QSOX1 leads to a decrease in cell proliferation, clonogenic capacities and promotes adhesion
to the extracellular matrix. QSOX1 also reduces the invasive potential of cells by reducing cell migration and
decreases the activity of the matrix metalloproteinase, MMP-2, involved in these mechanisms. Moreover, in vivo
experiments show that QSOX1 drastically reduces the tumor development.
Conclusions: Together, these results suggest that QSOX1 could be posited as a new biomarker of good prognosis
in breast cancer and demonstrate that QSOX1 inhibits human breast cancer tumorogenesis.
Introduction
The Quiescin Sulfhydryl Oxidase 1 (QSOX1) gene was
identified by our group in primary culture of guinea pig
endometrial glandular epithelial cells [1]. The human
gene is located on chromosome 1 (1q24) and encodes
two major isoforms by alternative RNA splicing:
QSOX1S (66 kDa) and QSOX1L (82 kDa) [2]. The short
transcript appears to be ubiquitous, whereas the expres-
sion of the longer form seems to be tissue specific [3].
The longer form of the QSOX1 protein retains a poten-
tial transmembrane segment that could allow for
anchorage to the membrane. The QSOX1 N-terminus
contains a sequence targeting the nascent protein to the
endoplasmic reticulum. Moreover, no signal for perma-
nent retention in the endoplasmic reticulum (KDEL
sequence) was identified, suggesting an extracellular des-
tination [4]. In addition, QSOX1 proteins have been
detected in the endoplasmic reticulum, the Golgi appara-
tus and the secretion vesicles [5]. These proteins can also
be found in culture supernatant and in extracellular
spaces, confirming that they are secreted [1].
QSOX1 is the product of an ancient fusion between
thioredoxin domains and Flavin Adenine Dinucleotide
(FAD) -binding module, ERV/ALR. A first CXXC motif
is located in N-terminus and can act as a reducer or an
oxidant. The other CXXC motif is located in a FAD
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domain within C-terminus [6]. The QSOX1 protein
belongs to a family of FAD sulfhydryl oxidases and cat-
alyzes the oxidation of thiols to disulfides. In vitro,
enzymatic studies on avian QSOX1 have demonstrated
that this enzyme is able to both catalyze disulfide
bridges of a large array of monothiol substrates (such
as glutathione) and reduce proteins and peptides [7,8].
Moreover, it seems that QSOX1 is not a disulfide iso-
merase but instead assists the Protein Disulfide Isomer-
ase (PDI) by establishing disulfide links in mature
proteins [9,10].
Previous reports showed that serum depletion-induced
quiescence, as well as cell contact inhibition, led to a
QSOX1 mRNA accumulation in guinea pig endometrial
glandular epithelial cells [1] and in human lung fibro-
blasts [3]. These experimental data suggest that QSOX1
could be involved in the negative control of the cell cycle.
Furthermore, in our laboratory it was demonstrated that
over-expression of guinea pig QSOX1-S in MCF-7 cells
decreased the cellular proliferation and protected cells
against oxidative stress [11]. It is now known that cellular
damage due to an accumulation of Reactive Oxygen Spe-
cies (ROS) leads to tumorogenesis [12,13]. By the redu-
cing activity of its first CXXC motif, QSOX1 could
prevent tumorogenesis by down-regulating ROS levels in
cells.
Another study suggested that QSOX1 could take part
in the cell anchorage mechanism. Indeed, increased
mRNA levels have been detected in human lung fibro-
blast when cell/plate or cell/cell adhesion was disturbed
by a mechanical or chemical action [14].
Several systemic studies have demonstrated an altera-
tion of QSOX1 expression in cancer cell models. In fact,
one study demonstrated the presence of peptide frag-
ments of QSOX1 at highly significant rates in plasma
from patients suffering from pancreatic cancer [15].
Moreover, very recently, it was reported that QSOX1
could promote invasion of pancreatic tumor cell lines by
activating matrix metalloproteinase [16]. In another, a
correlation was observed between the overexpression of
QSOX1 and the initiation of prostate tumor growth [17].
On the other hand, QSOX1 expression is repressed by
epigenetic regulation, especially by histone deacetylation
in a cell model of endothelial tumors. Moreover, this
down-regulation seems to be necessary for angiogenesis,
an essential phenomenon for metastasis development
[18]. These data suggest an involvement of QSOX1 in the
mechanisms of carcinogenesis.
In the present study, QSOX1 mRNA expression was
investigated in a retrospective cohort of 217 invasive ductal
carcinomas (IDC) of the breast. The impact of the QSOX1
expression on characteristic phenotypes of breast cancer
cells and tumor growth was subsequently determined.
Materials and methods
Clinical analysis
Patients and tumor characteristics (Table 1)
The study included a retrospective cohort of 217
patients with invasive ductal carcinomas of the breast.
This cohort was derived from the population described
previously [19]. Estrogen receptor (ER) and progesterone
receptor (PgR) were assayed in cytosol using the radioli-
gand reference method [20]. PAI-1 (Plasminogen activa-
tor inhibitor-1) was measured in Triton extract by the
enzyme-linked immunoassay (PAI-1, Imubind #821,
American Diagnostica, Stamford, CT, USA) as elsewhere
described [21]. Studies involving human primary breast
tumors were performed according to the principles
embodied in the Declaration of Helsinki. Tissue biopsies
were obtained as part of surgical treatments for the hor-
mone receptor content determination. Remaining sam-
ples were included anonymously in this study. Ethical
approval and consent were not required due to the rou-
tine nature of the procedure.
Reverse Transcriptase Quantitative PCR (RT-qPCR) analysis
Detailed information on RNA extraction and RTqPCR has
been previously described [19]. The QSOX1 primers used
were: forward, 5’-GGAAGCTT CTGGAAGTCGTG-3’ and
reverse, 5’-CAAAAGACCAGGCTCAGAGG-3’ for ampli-
fication of a 211 bp fragment (GenBank NM_002826). The
QSOX1 target concentration was expressed relative to the
concentration of the GAPDH housekeeping gene [19].
Statistical analysis
The median follow-up at the time of analysis was 54
months (range: 2 to 109). Patients were followed up for
metastasis relapse (nodal or distant metastasis and local
recurrence were relapse). Analysis of the distribution of
QSOX1 RNA expression in relation to usual prognostic
parameters was performed using the Mann-Whitney or
Kruskall Wallis test. Metastasis free survival probabilities
were estimated using Kaplan Meier estimators and were
compared using the log-rank test. These analyses were




Cell culture reagents were purchased from Invitrogen
(Cergy Pontoise, France). Miscellaneous reagents were
purchased from Sigma Aldrich (L’Isle d’Abeau Chesnes,
France). Specific inhibitor of matrix metalloproteinase
(MMP)2 was purchased from Millipore (Molsheim,
France). The following antibodies were used: for Western
blotting, polyclonal anti-rat QSOX1 [4] diluted at 1:7,500,
for immunohistochemistry, polyclonal anti-human
QSOX1 (Proteintech Group, Inc., Chicago, IL, USA)
diluted at 1:100, polyclonal anti-MMP-2 (Cell Signaling
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Technology, Danvers, MA, USA) diluted at 1:2,000, poly-
clonal anti-actin (Sigma Aldrich) diluted at 1:5,000 and
polyclonal anti-rabbit (P.A.R.I.S, Compiègne, France)
diluted at 1:10,000.
Cell culture
Cells were cultured in DMEM (Dulbecco’s Minimum
Essential Medium) supplemented with 2 mM L-Glutamine,
100 μg/ml penicillin, 100 μg/ml streptomycin and 5% fetal
calf serum (FCS) and kept in a humidified 5% CO2water
saturated atmosphere. Cell viability was estimated by
counting Trypan blue excluding cells.
Plasmid construction, small-hairpinRNA (shRNA)
experiments and transfection
The pcDNA3.1-QSOX1S plasmid was constructed by
cloning the coding sequence of QSOX1-S splice var-
iant 2 (AF361868) between the EcoRV and BamHI
sites of pcDNA™3.1/Hygro(-) (Invitrogen). MCF-7
cells were transfected with the pcDNA3.1 and the
pcDNA3.1-QSOX1S expression plasmids using Lipo-
fectamine 2000 (Invitrogen), according to the manufac-
turer’s instructions. Then, cells were selected with
200 μg/ml Hygromycin B (PAA, Les Mureaux, France).
shRNA vectors from the Mission human shRNA
hQSOX1 clone sets (Sigma Aldrich) were used:
shQSOX1-1 (TRCN0000064183), shQSOX1-2 (TRCN-
0000064185), and appropriate control vector: shC
(SHGLYNM_001004128). Lipofectamine LTX (Invitro-
gen) was used to stably transfect MDA-MB 231 cells,
according to the manufacturer’s recommendations.
Clones were selected with 1 μg/ml Puromycin (Sigma
Aldrich).
QSOX1 mRNA detection and level analysis
Total RNAs were extracted as previously described [11].
RTqPCR was performed with the Step One Real Time
PCR System (Applied Biosystems, Carlsbard, CA, USA),
using the SYBER Green PCR Master Mix (Applied Biosys-
tems). Target (endogenous and plasmid encoded QSOX1
mRNA) and endogenous control (H3.3 like histone H3B-2
(H3B-2)) amplifications exhibited 100 ± 5% efficiency (R2
>99% for the standard curve); QSOX1 primer sequences
were: hQSOXE+Ts1: 5’-GCCACCCTCAACTTCCT-
CAAG-3’, hQSOXE+Trev1: 5’-ACCCAGCTGCAGGG
AAGTC-3’; H3B-2 primer sequences were: HisI: 5’-GCT
AGCTGGATGTCTTTTGG-3’, HisN: 5’-GTGGTAAAG-
CACCCAGGAA-3’). Each sample was analyzed in tripli-
cate and then differences in the expression of each gene
were quantified using the ∆∆Ct approach using endogen-
ous control.
Immunoblotting
SDS-polyacrylamide gel electrophoresis and transfer
of proteins onto PVDF membranes (Bio-Rad, Marnes-la-
Coquette, France) were performed using standard proto-
cols. The antibodies were used at the previously indicated
dilution. Immunoreactive bands were detected using goat
horseradish peroxidase (HRP)-coupled secondary anti-
rabbit antibodies (1:10,000 in antibody blocking buffer)
and ECL Plus reagent (GE Healthcare Life Sciences,
Saclay, France), according to the manufacturer’s protocol.
Blots were stripped by incubation in stripping buffer
(62.5 mM Tris, pH 6.7, 100 mM b-mercaptoethanol and
2% SDS) for 30 minutes at 50°C, blocked again in TBST
buffer containing 5% non-fat milk and then probed a
second time with polyclonal anti-actin.
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded tissue blocks from
patients whom underwent surgical resection for invasive
ductal carcinoma and normal breast tissue were sec-
tioned at 5 μm thickness using water flotation for tissue
section transfer and dried overnight at room tempera-
ture. The slides were de-waxed, rehydrated and subjected
to heat induced epitope retrieval using a proprietary
citrate based retrieval solution for 40 minutes. Endogen-
ous peroxidases were blocked. QSOX1 detection was per-
formed as described in Antwi et al. [15]. QSOX1 location
analysis was performed by Dr. Viennet, a board-certified
pathologist.
Cell-Matrix Adhesion Assay
Cells were incubated at 37°C for 60 minutes at a density
of 4 × 105 cells/well in serum-free DMEM on non-coated
well plates (three wells/cell line: one well to control the
number of seeded cells and the two others for technical
duplicates). After washing, adherent cells were collected
and pelleted down. Then, cells were counted with Malas-
sez cell. Results were expressed as the ratio between plate
adhering cells and total seeded cells and reported as
mean ± SD of triplicate determinations.
Colony formation assay
Cells were plated in six-well tissue culture plates at a
density of 50 cells/cm². After 28 days, colonies were fixed
with ethanol and stained with 2% crystal violet, washed
with water to remove the excess dye, and imaged by a
scanner. Quantitative changes in clonogenicity were
determined by counting the colonies, using Bio-Rad
Vision-Capt software.
Anchorage independent cell proliferation
Cells were seeded at a density of 6 × 104 cells per 35-mm
cell culture dish in 0.3% agar. After 28 days, the top agar
cell layers were covered with culture medium containing
5% FCS. Images from four representative fields of each
well were taken and analyzed.
Cell migration and invasion assay
For the migration assay, 105 cells were suspended in 300
μL serum-free medium and added into the upper cham-
ber of the Boyden modified chamber™ (SPL Life
Sciences, Pocheon-si, Korea). For the invasion assay, 105
cells in 200 μL serum-free medium, in the presence or
absence of 10 μM of a MMP-2 specific inhibitor, cis-9-
Octadecenoyl-N-hydroxylamide (OA-Hy) [22,23], were
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added into the upper chamber. Five hours before cell seed-
ing, 50 μL of extra cellular matrix (ECM) gel (1 mg/ml)
were added to the upper chamber. Thereafter, the cells
were incubated 24 h for migration or invasion assay. The
cells on the upper surface were removed using a cotton
bud. The remaining invading cells were fixed, stained with
2% crystal violet and the images from four representative
fields of view (FOV) of each membrane were taken. The
invasive cells in the lower chamber were counted.
Zymography assay
The gelatinase activity of MMPs in the serum-free media
was analyzed by gelatin-zymography. A total of 105 cells
suspended in 250 μl were plated onto a 24-well plate.
The serum-free medium was collected after 12 h of incu-
bation for MCF-7 cells and 24 h for MDA-MB-231 cells.
HT-1080 conditioned media was used as positive control.
The proteins from the conditioned media were 100-fold
concentrated by acetone precipitation and solubilized in
Laemmli Buffer (without b-mercaptoethanol). Then, pro-
teins were separated by SDS PAGE electrophoresis using
10% (w/v) acrylamide gels containing 1% (w/v) gelatin at
20 mA. Gels were rinsed in Triton X-100 (2.5%, v/w) and
incubated in 50 mM Tris-HCl, 150 mM CaCl2 and 5 μM
ZnCl2 (pH 8.0) at 37°C for 16 h. Gels were stained with
0.25% (w/v) Coomassie brilliant blue. Digested areas
appeared clear on a blue background, indicating the loca-
tion of active MMPs.
Xenograft experiments
CIEA NOG mice were obtained from Taconic (German-
town, NY, USA) and maintained in the UMR1098 animal
facility (agreement number #C25-056-7). Approval for
animal experimentation and care was received from the
Services Vétérinaires de la Santé et de la Protection Ani-
male delivered by the Ministère de l’Agriculture, Paris,
France and experimental procedures were approved by a
local ethic committee.
A total of 2 × 106 cells of different cell lines (MDA-MB-
231 shC and MDA-MB-231 shQSOX1-1) resuspended in
100 μL of PBS per mouse were inoculated subcutaneously
in NOG mice (n = 5 per group) and tumor growth was
monitored biweekly in each group. Tumor volume was
calculated by the formula V = ½ a × b2, where a is the
longest tumor axis and b is the shortest tumor axis. When
tumors reached 1 cm in diameter, mice were sacrified and
each tumor was fixed in formol and photographed. During
the sacrifice, photos have been taken in order to keep
proof of where tumors developed.
Results
QSOX1 localization in normal and in breast cancer tissues
IHC experiments were performed on sections of normal
mammary gland and invasive ductal carcinoma (IDC).
Results in Figure 1 show a QSOX1 expression in human
normal breast tissue: QSOX1 is localized at the level of
milk ducts and channels of the ductulo-lobular units
(Figure 1A); the labelling is perinuclear and at the apex
of the constituent cells of these histological structures
(Figure 1B), suggesting a localization in different com-
partments of the secretory pathway. In the tissues from
IDC, a diffuse cytoplasmic labelling of QSOX1 was
observed in tumor cells (Figure 1C, D). In non-cancer-
ous cells from IDC tissues section, QSOX1 labelling
appeared as a punctate perinuclear and apical staining
in the ductulo-lobular units (Figure 1E), as observed in
normal mammary glands. A lack of labelling was noted
in stromal cells and adipocytes, whether observing sec-
tions from normal or pathological tissue (Figure 1A, C).
QSOX1 mRNA expression in breast cancer
We investigated QSOX1 mRNA expression in a cohort of
217 invasive ductal carcinomas of the breast. The mean
QSOX1 value measured by RTqPCR was 3.56 and the
median was 2.84 (range: 0.25 to 19.89). Table 1 shows
the median value of QSOX1 in relation to tumor charac-
teristics that are usually linked to the prognosis. Indeed,
the median QSOX1 expression value was significantly
lower in the patients with pejorative prognostic factors:
premenopausal status, SBR grade III, negative ER or PgR,
and/or high PAI1 level (Figure 2A, Kruskall Wallis test,
P-value <0.001).
The Kaplan Meier curves were constructed after seg-
mentation into two groups on the basis of the QSOX1
expression cut-off equal to the upper threshold of the
first tertile. This cut-off, that is, 2.11, allowed the discri-
mination between high and low QSOX1 status. It was
observed that high values of QSOX1 expression were
related to a good prognosis (Figure 2B, P-value = 0.007).
Expression of hQSOX1 in breast cancer cell lines
Coppock and coworkers have previously observed, by
Northern blotting, that QSOX1 is expressed at a low level
in MCF-7 and MDA-MB-453 cells and at a high rate in
MDA-MB-231 breast cancer cell lines [3]. First, we ana-
lyzed expression of the QSOX1 gene by RTqPCR in these
cell lines. Our results indicate that the relative fold of
QSOX1 expression in MDA-MB-231 and MCF-7 cells was
253.5 ± 1 (mean ± SD) and 4.2 ± 0.5, respectively com-
pared to MDA-MB-453 cells (Figure 3A). These results
were confirmed at the protein level. In fact, QSOX1S
expression is very weak in MDA-MB-453 and MCF-7 cells
and high in MDA-MB-231 cell lines (Figure 3B).
To investigate the function of hQSOX1S in the breast
cancer cell line, we established stably transfected mono-
clonal MCF-7 cells overexpressing hQSOX1S (MCF-7
QSOX1S-1 and MCF-7 QSOX1S-2 lines). We then mea-
sured the level of QSOX1S expression in MCF-7 Con-
trol (MCF-7 C) and MCF-7 QSOX1S-1 and MCF-7
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QSOX1S-2 lines under standard culture conditions. The
relative fold of QSOX1 expression was determined by
RTqPCR. MCF-7 QSOX1S-1 and MCF-7 QSOX1S-2
lines showed an increase of 186% ± 11 (mean ± SD) and
180% ± 11, respectively, compared to MCF-7 C cells
(Figure 3C). QSOX1 overexpression was also assessed at
the protein level. The signal corresponding to hQSOX1S
was strongly increased in MCF-7 QSOX1S-1 and MCF-
7 QSOX1S-2 lines as compared to MCF7 C (Figure 3D).
Our second approach to studying the function of
QSOX1 consisted of silencing QSOX1 expression. A
series of RNA interference experiments using shRNA
vectors were then performed in MDA-MB-231 cells.
After RTqPCR analysis, two shRNA QSOX1 vectors
(shQSOX1-1 and shQSOX1-2), inducing 55% ± 4 (mean
± SD) and 92% ± 1 decreases of the QSOX1 expression,
respectively, were selected (Figure 3E). Results obtained
by Western blotting showed a decrease in the signal
corresponding to QSOX1S in the knock-down cell lines
compared to the control (Figure 3F). MDA-MB-231
shQSOX1-2 harbors a higher extinction of the protein
than MDA-MB-231 shQSOX1-1, as observed at the
mRNA level.
QSOX1 decreased cell proliferation and colony formation
Cancer is characterized by an enhancement of cell pro-
liferation. To determine the involvement of QSOX1 in
cell proliferation, 104 cells were initially seeded and then
the live cell number was measured. MCF-7 QSOX1S-1
and MCF-7 QSOX1S-2 proliferated less than MCF-7 C.
Indeed, after five days of culture, living cell number
increased 3.6-fold for MCF-7 C, 1.9 for MCF-7
Figure 1 QSOX1 localization in normal and breast cancer tissues. Anti-QSOX1 IHC on normal mammary gland section (A, B) and on
invasive ductal carcinoma (IDC) section (C, D, E). (A) The first arrow (1) indicates the presence of labelling in normal breast ductulo-lobular units.
(B) Perinuclear and apical staining in ductulo-lobular unit cells. (C) The second arrow (2) indicates a labelling in tumor cells from IDC and the
third arrow (3) shows the absence of labelling in stroma cells. (D) Diffuse cytoplasmic staining in tumors cells. (E) Perinuclear and apical labelling
in non cancerous cells from IDC.
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QSOX1S-1 and 1.8 for MCF-7 QSOX1S-2 (Figure 4A).
After one week of culture, the number of MDA-MB-231
shQSOX1-1 or shQSOX1-2 living cells was strongly
increased compared to MDA-MB-231 shC (Figure 4B). In
fact, the living cell number increased 19.6-fold for MDA-
MB-231 shC, 34.3-fold for MDA-MB-231 shQSOX1-1
and 39.8-fold for MDA-MB-231 shQSOX1-2.
While over-expression of hQSOX1S reduced cell growth
by about two-fold compared to control, knock down of
QSOX1 increased cell growth by about two- fold.
The enhancement of clonogenic capacities is a specific
characteristic to cancer cells. In order to evaluate the
survival, proliferation capacities and self-renewal of our
cell models, we performed clonogenicity tests [24]. After
21 days of standard culture conditions, QSOX1 overex-
pression led to 3.2-fold and 3-fold decreases of MCF-7
QSOX1S-1 and MCF-7 QSOX1S-2 colonies, respec-
tively, compared to MCF-7 C (Figure 4C). In contrast,
QSOX1 down expression enhanced the number of new
colonies by 1.7- and 2-fold compared to MDA-MB-231
control cells (Figure 4D).
Inhibition of colony formation was correlated with the
overexpression of QSOX1S while an enhancement of
newly-formed clones was associated with QSOX1 knock
down.
Another mechanism of tumor aggressiveness is the
anchorage independent cell growth [25]. As such, we
studied the role of QSOX1 on anchorage-independent
growth. MCF-7 or MDA-MB-231 cell lines were plated
in soft agar and incubated for two weeks before deter-
mining the size and number of colonies. The number of
colonies decreased by 62.1% ± 7.2 (means ± SD) for
QSOX1-1 and 64.4% ± 10.3 for QSOX1S-2 compared to
the control (Figure 4E). Inversely, there was an enhance-
ment of 158% ± 14.5 and 270% ± 8.5 colony number
compared to shC for shQSOX1-1 and shQSOX1-2,
respectively (Figure 4F). QSOX1 seems to play a role
in the negative control of cell growth, anchorage
Table 1 QSOX1 mRNA expression in relation to the usual
prognostic factors in 217 breast IDC
Characteristics n % median P-value
Menopausal status Pre 71 32.7 2.56
Post 146 67.3 3.31 0.003
Tumor size (mm) <20 90 41.5 3.08
≥20 120 55.3 2.62 0.229
ND 7 3.2 3.38
Lymph node status pN0 101 46.5 3.18
pN+ 116 53.5 2.64 0.444
SBR Grade I 30 13.8 4.25
II 115 53.0 3.14
III 58 26.7 1.74 <0.001
ND 14 6.5 2.42
ER status Positive 179 82.5 3.17
Negative 38 17.5 1.51 <0.001
PgR status Positive 169 77.9 3.17
Negative 48 22.1 1.97 <0.001
PAI-1 status* Low 153 70.5 3.18
High 44 20.3 1.46 <0.001
ND 20 9.2 2.77
P-values correspond to Mann-Whitney test or Kruskall Wallis test. ER, estrogen
receptor; ND, Not Determined; PgR, Progesteron receptor; SBR, Scarff Bloom
Richardson. *Low: ≤75% quartile; High: >75% quartile.
Figure 2 Expression of QSOX1 mRNA in a cohort of 217
invasive ductal carcinomas of the breast. (A) Box plots of QSOX1
expression in relation to the histological grade (Kruskall Wallis test, P
<0.001); (B) Kaplan-Meier curves for metastasis-free survival
probabilities according to QSOX1 expression categorized with a cut-
off equal to the upper threshold of the first tertile. Low: < first
tertile, High: ≥ second tertile. SBR: Scraff Bloom Richardson;
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independent cell proliferation and in the capacity to
form new colonies.
QSOX1 increased cell/matrix adhesion
Loss of cell adhesion to the matrix is often associated
with tumor aggressiveness. We then tested cell adhesion
to extracellular matrix by determining the number of
adherent cells and cells remaining in the supernatant
one hour after seeding. Figure 5 indicates the ratio
between adherent cells and total seeded cells. Overex-
pression of QSOX1-S in MCF-7 cells led to a higher
number of adherent cells, compared to MCF-7 C, one
hour after seeding: 76% ± 2 (means ± SD), 93% ± 3 and
28% ± 4 of adherent cells in MCF-7 hQSOX1S-1, MCF-
7 hQSOX1-2 and MCF-7 control, respectively (Figure
5A). Conversely, numbers of MDA-MB-231 shQSOX1-1
and shQSOX1-2 adherent cells were lower, compared to
control: 52.4% ± 1, 44% ± 7 and 81.5% ± 1 of adherent,
MDA-MB-231 shQSOX1-1, shQSOX1-2 cells, and shC
respectively (Figure 5B). Interestingly, 24 h after seeding,
no difference between the numbers of adherent cells in
overexpressing or knock down models compared to
Figure 3 Analysis of QSOX1 expression in breast cancer cell lines. (A, C, E) After reverse transcription, relative QSOX1 mRNA expressions
were determined by qPCR (C: MCF-7; E: MDA-MB-231). H3B-2 mRNA was used for normalization. Data are means ± S.D. of three independent
experiments. *P <0.05, compared to control (Wilcoxon test). (B, D, F) Western blot analysis of QSOX1 expression. Total proteins (50 μg) were
separated on SDS-PAGE and transferred to PVDF membranes (D: MCF-7; F: MDA-MB-231). Proteins were detected using anti-QSOX1 and anti-
actin antibodies. NS, Non Specific.
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Figure 4 Effect of QSOX1 on cell proliferation and colony formation. (A, B) Cells were plated at 5,000 cells/cm². Cell viability was estimated
by counting Trypan blue excluding cells. Data are expressed relative to the living cell number at day 0. Values are expressed as mean ± SD for
three experiments. (C, D) For a colony formation assay, 500 cells were plated and 28 days later, cells were fixed and stained with 2% crystal
violet. Quantitative changes were evaluated by counting using Vision Capt software. (E, F) Colony assays in soft agar were done to evaluate the
effects of QSOX1 on anchorage independent cell proliferation. Cells were embedded in 0.3% agar and the agar cell layers were covered with 1
ml medium containing 5% FCS. After 28 days of growth, the colonies were photographed. Pictures of colonies were superposed with a Malassez
cell picture in order to determine colony size. Results indicated number and colony size from four representative fields of each well. * P <0.05,
compared to control (Wilcoxon test). These experiments are representative of three separate assays.
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their respective controls was observed (data not shown).
These results suggested that QSOX1 could increase the
speed of adhesion of cells to the extracellular matrix.
QSOX1 decreased invasion
Since invasion is one of the key steps in tumor and
metastasis development [26], it was studied with the
modified “Boyden chamber” technique in the presence
of Matrigel [27]. One day after seeding, 32 ± 3.1 (means
± SD) MCF-7 C cells were detected on the membrane’s
inferior face whereas only 7 ± 2 MCF-7 hQSOX1S-1
cells and 9 ± 3 MCF-7 hQSOX1S-2 cells were counted
(Figure 6A). As regards the MDA-MB-231 model, only
4 ± 0.6 shC cells invaded the lower chamber compared
to 19 ± 3 shQSOX1-1 cells and 25 cells ± 3 shQSOX1-2
cells through the membrane (Figure 6B). Thus, overex-
pression of QSOX1 in MCF-7 cells decreased cell inva-
sion, whereas QSOX1 knock-down in MDA-MB-231
increased this cellular process. We also observed that
invading cells with high QSOX1 expression were
rounded, whereas those with low QSOX1 expression
presented a stellate morphology (Figure 6A, B).
As degradation of the extracellular matrix by matrix
metallo proteinases (MMPs) is characteristic of the inva-
sion process [28], we studied the activity and secretion of
MMP-2 and MMP-9, enzymes involved in the mechan-
ism of invasion [29], by a zymography test and western
blotting. Results in Figure 6C show the presence of pro
and active MMP-2 in the MCF-7 C culture medium and
an important decrease of intensity of the two bands in
the MCF-7 QSOX1S-1 and MCF-7 QSOX1S-2 culture
media (Figure 6CZY). Conversely, the bands correspond-
ing to the pro and active MMP-2 were more intense in
MDA-MB-231 shQSOX1-1 and shQSOX1-2 than in the
control (Figure 6DZY). These results suggest that QSOX1
decreased both pro and active MMP-2 level in extracellu-
lar medium and thus the rate of MMP-2 activity. It is
noteworthy to mention that MMP-9 activity was less
intense in our models but the same activity variations as
for MMP-2 were observed (data not shown). To deter-
mine if MMP-2 activity variations were due to a modula-
tion of MMP-2 activation or to an increase in their
expression or secretion, we analyzed the presence of this
protein in the different culture media. As shown in Wes-
tern blotting, Figure 6C, MMP-2 protein was detected in
MCF-7 C conditioned medium extract but not in that of
MCF-7 QSOX1S-1 and QSOX1S-2. Moreover, a very low
level of MMP-2 was detected in MDA-MB-231 shC cul-
ture medium (Figure 6DWB) whereas it was greatly
increased in those of MDA-MB-231 shQSOX1-1 and
MDA-MB-231 shQSOX1-2. Quantification of MMP-2
mRNA by RTqPCR was performed but neither the over-
expression or knock-down of QSOX1 influenced MMP-2
mRNA level (data not shown). Thus, QSOX1 could
attenuate MMP-2 extracellular activity by probably acting
on its stability and/or its secretion.
In order to examine if the observed differences in inva-
sion assays were associated with a modulated activity of
Figure 5 Effect of QSOX1 cell/matrix adhesion. MCF-7 (A) or MDA-MB-231 (B) cells were incubated at 37°C for 60 minutes at a density of 4 ×
105 cells/well in serum-free DMEM. One hour later, adherent cell numbers were determined by counting Trypan blue excluding cells. Results
were expressed as the ratio between cells adhered on the plate and total seeded cells and reported as the mean ± S.D. of triplicate
determinations. * P <0.05, compared to control (Wilcoxon test). This experiment is representative of three separate assays.
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Figure 6 Effect of QSOX1 on invasiveness. (A, B) Cells were seeded on polycarbonate filter coated with Matrigel, in the presence/or not of a
specific inhibitor of MMP-2 (OA-Hy) at 10 μM and incubated for 24 h and analyzed as described in Materials and Methods. Inserts were stained
with 2% crystal violet and photographed. * P <0.05, compared to control (Wilcoxon test). (C, D)ZY Gelatin Zymography of matrix-
metalloproteinase in conditioned medium. Cells were seeded and the media were collected after 24 h and 12 h of serum starvation for the
MCF-7 and MDA-MB-231 cell lines respectively. Conditioned medium from HT-1080 cell line was used as positive control. Vertical line has been
inserted to indicate a repositioned gel lane. (C, D)WB Blotting identification of MMP-2 in protein extracts from conditioned culture medium. (E, F)
Cells were seeded on polycarbonate filters coated without ECM and incubated for 24 h and analyzed as described in (A). * P <0.05, compared to
control (Wilcoxon test). These experiments are representative of three separate assays.
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MMP-2, we performed invasion assays in the presence of
a specific inhibitor of MMP-2. One day after seeding, 1.5
± 0.6 (means ± SD) MCF-7 C cells were detected on the
membrane’s inferior face and, as MCF-7 C, only 1.25 ±
0.5 MCF-7 hQSOX1S-1 cells and 1.25 ± 0.5 MCF-7
hQSOX1S-2 cells were counted (Figure 6A). With
respect to the knock-down model, 1.3 ± 0.6 shC cells
invaded the lower chamber and 3.7 ± 0.6 shQSOX1-1
cells and 3.3 cells ± 0.6 shQSOX1-2 cells passed through
the membrane (Figure 6B). Inhibition of MMP-2 results
in a loss of all differences in variations of invasion
between different cancer cell models. These results show
that QSOX1 down-regulates invasion, probably in part
by negatively regulating MMP-2 activity.
Since the capacity of cells to migrate through a physio-
logical membrane is also a component of invasion, cell
migration was studied using the modified “Boyden
Chamber”. Cells were seeded in a Boyden chamber lack-
ing the Matrigel layer and cells able to cross the mem-
brane were counted 24 h later. Cell number was 40 ± 6
(means ± SD) for MCF-7 C, and 9 ± 3 and 11 ± 4 for
MCF-7 hQSOX1S-1 and MCF-7 hQSOX1S-2, respec-
tively (Figure 6E). In our knock-down model, there were
only 108 ± 2 shC cells that passed through the mem-
brane, whereas 147 ± 1 shQSOX1-1 cells and 226 ± 3
shQSOX1-2 cells were counted. QSOX1 knock-down in
MDA-MB-231 cells increases the cellular motility (Figure
6F). Interestingly, the extent of the phenotypes observed
in our knock-down models was inversely related to
QSOX1 expression levels. Thus, it appears that QSOX1
also reduced cell migration.
QSOX1 suppressed tumor development in vivo
Tumorigenic properties of the QSOX1 knock-down
models were analyzed in CIEA NOG mice. Tumor size
was monitored for two months after inoculation. Results
showed that decreased expression of QSOX1 led to a
strong enhancement of the size (Figure 7A) and growth
of the tumors (Figure 7B). In fact, 42 days after inocula-
tion, the mean volume of MDA-MB-231 shQSOX1-1
tumors was 2.65 times higher than the mean volume of
tumors obtained in the CIEA NOG control mice. Thus,
in vivo, QSOX1 drastically reduced tumor growth. In
addition, during the excision of tumors produced from
the cell line MDA-MB-231 shC, we observed that
tumors had developed just under the skin of animals
while tumors from the MDA-MB-231 shQSOX1-1 cell
line had developed in the subjacent muscle tissue (Addi-
tional file 1). This suggests that QSOX1 could be unfa-
vorable for tumor invasion.
Discussion
In this study, we provide, for the first time, an insight
into the QSOX1 expression level in breast tumors
and into its role in breast cancer cells and tumor
development.
Even if the enzymatic function of QSOX1 is well
described in the literature, its biological function is not
clearly established. In fact, QSOX1 expression is differ-
entially modulated in some cancers. It turns out that
QSOX1 is overexpressed during the early stages of pros-
tate cancer, and in pancreatic tumor cells [15-17]. How-
ever, it has also been shown that QSOX1 is down-
regulated in an endothelial cancer cell model [18]. As
such, we decided to investigate the QSOX1 expression
in normal and cancerous human breast tissues.
Prior to our study, it was not previously reported
where QSOX1 was expressed in breast tissues. IHC
results showed that the protein was expressed in the
endomembranous system in epithelial cells, but not in
stroma cells and in adipocytes. Results were consistent
with the fact that QSOX1 is a protein specifically
expressed in epithelial cells and secreted [1,30]. The dif-
ferential localization of QSOX1 in normal and cancer
cells could be due to post-translational modifications
and/or a differential regulation of the expression of
Figure 7 QSOX1 reduces breast cancer xenograft formation.
2.106 MDA-MB-231 shC and MDA-MB-231 shQSOX1-1 cells were
injected subcutaneously in CIEA NOG mice (n = 5 per group).
Tumor volume was calculated by the formula V = ½ a × b2, where
a is the longest tumor axis, and b is the shortest tumor axis. (A) 42
days after injection, tumors were fixed in formol and photographed,
(B) 21 days after injection, the evolution of the tumor volume was
measured biweekly. * P <0.05, compared to control (Wilcoxon test).
This experiment is representative of two separate assays.
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QSOX1 isoforms. The signal surrounding tumor cells
could also be due to an epithelial cell depolarization,
causing a loss of punctuate labeling and the appearance
of a diffuse staining. Moreover, QSOX1 is expressed in
pancreatic tumor cells and not in non-cancerous periph-
eral cells [16]. Together, these results indicate that
QSOX1 is not constitutively expressed in different tis-
sues, suggesting that the cellular role for this protein
may also be tissue-dependent.
As QSOX1 was expressed in breast cancer tissues, we
assessed if its expression level could be correlated to the
outcome of breast cancer patients. Thus, we studied the
QSOX1 mRNA expression in a retrospective cohort of
217 invasive ductal carcinomas of the breast. It appears
that breast tumors presenting good prognostic criteria,
such as low histological grade and steroid receptor-posi-
tive status, express a high level of QSOX1 mRNA (Figure
1A and Table 1). Furthermore, Kaplan-Meier curves
(Figure 1B) showed that patients with high QSOX1 levels
presented a significantly better metastasis-free survival
compared to patients with low QSOX1 mRNA levels.
These data suggest that the QSOX1 expression level
could negatively correlate with the aggressiveness of
breast tumors.
To determine the extent of association between
QSOX1 expression and breast cancer patient outcome,
we investigated the roles of QSOX1 on characteristic
cancer cell phenotypes in MCF-7 overexpressing
QSOX1 and MDA-MB-231, in which QSOX1 expres-
sion is knocked down. It must be underlined that
QSOX1 levels are higher in the invasive MDA-MB-231
cells compared to the more indolent MCF7 cells. Differ-
ences between these two cell lines are not limited to
basal QSOX1 expression but also include the expression
of several genes, such as steroid hormone receptors and
the receptor 2 of the epidermal growth factor [31].
Therefore, QSOX1 expression could not be responsible
in itself for the difference in aggressiveness of these cell
lines.
After validation of our cellular models, we investigated
the role of QSOX1 on proliferation, clonogenic capaci-
ties and invasion. Above all, it is interesting to note that
all observed phenotypes obtained with the overexpres-
sion of QSOX1 were opposite of those obtained with
the QSOX1 knocked-down model. Moreover, in the lat-
ter cell model, the intensity of the effect was correlated
to the extent of QSOX1 knock-down.
We report in this study that QSOX1 inhibits breast
cancer cell proliferation. These data are in accordance
with previous studies showing that QSOX1 decreased
epithelial and endothelial cell proliferation [11,18]. The
fact that QSOX1 was induced in quiescent WI38 fibro-
blasts, but not in cycling lung fibroblasts, suggests that
it could act in the negative control of the cell cycle and
reinforces the idea that it could downregulate cell prolif-
eration [3]. Conversely, Katchman and coworkers sug-
gested that a QSOX1 knock-down in different pancreatic
cancer cells decreased proliferation. But, cell cycle ana-
lyses did not give clear conclusions about QSOX1 role
on cell cycle control [16]. All these results suggested that
QSOX1 role on proliferation and cell cycle could be cell
type or tumor stage dependent.
The study of cancer cell proliferation is generally per-
formed in parallel with the study of the cell clonogenic
capacity, often associated with tumor development
and establishment of metastases [32]. Thus, the fact
that QSOX1 reduced cell clonogenicity and anchorage-
independent growth is in accordance with our observa-
tions on proliferation. In addition, we studied the effect of
QSOX1 on cell-matrix adhesion, which is often disrupted
in breast cancer. Our findings demonstrate that QSOX1
increased cell adhesion to the extracellular matrix but
more specifically early in the adhesion process. Since
QSOX1 is implicated in protein folding, we can hypothe-
size that QSOX1 could enhance the folding or the addres-
sing of newly synthesized proteins implicated in cell
adhesion to the matrix. In fact, it is already known that
integrin activation can be mediated by thiol disulfide
exchanges within the extracellular domain of the beta sub-
unit [33,34], a process often performed by the Protein Dis-
ulfide Isomerase (PDI) [35,36]. QSOX1 could activate
integrins directly by creating a thiol-disulfide bond or
indirectly via an oxidation of PDI [9].
We showed in our retrospective cohort of invasive duc-
tal carcinomas of the breast that a high QSOX1 expression
is associated with low expression of a well-established
marker of migration and invasion phenotype in breast can-
cer: PAI1 (Table 1) [37]. In fact, the tumor cell must first
degrade basement membrane components before being
able to migrate and establish itself in another organ [38].
We demonstrated that QSOX1 decreased the ability of
cells to invade the Matrigel. Furthermore, a low QSOX1
expression level confers to the invading cells this stellate
morphology described as characteristic of a high meta-
static potential [39].
Considering that QSOX1 decreased cellular invasion,
we studied the activity of MMP-2 and MMP-9, enzymes
widely described to be involved in the mechanism of
invasion [29]. QSOX1 decreased both pro and active
MMP-2 level in extracellular medium and thus the rate
of MMP-2 activity. QSOX1 has also a lesser effect on
MMP-9 activity. Nevertheless, QSOX1 had no effect on
other MMPs implicated in the basal membrane degrada-
tion process, such as MMP-3 and MMP-7 [29] (data not
shown). It seems that QSOX1 reduced invasion by down-
regulating MMP-2 activity, since the effect of QSOX1 on
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invasion was no longer observable in the presence of a
specific MMP-2 inhibitor. The involvement of MMP-2 in
cell proliferation [40] could account for our results on
this cellular process.
The MMP-2 regulation is very complex and the role
of QSOX1 on this MMP remains to be determined. Our
results suggest that QSOX1 could attenuate MMP-2
extracellular activity by probably acting on MMP-2
secretion and/or stability without modifying the mRNA
level.
Thus, QSOX1 could inhibit MMP-2 activation by pro-
moting cell matrix adhesion. In fact, when cells do not
adhere to the matrix, integrin avb3 interacts with
MMP-2 and so participates to its activation [29]. The
TIMPs (Tissue Inhibitors of MetalloProteinases), present
six conserved disulfide bonds involved in their interac-
tion domains with MMPs [41]. QSOX1 could promote
disulfide bond formation in TIMPs, and thus their inter-
action with MMP-2, leading to its inhibition.
Interestingly, the activation and secretion of MMP-2
could also be positively regulated by oxidative stress
through the oxidation of its pro-peptide [41]. Since
QSOX1 protected cell against oxidative stress [11], it
could eventually prevent oxidation of the pro-peptide
and so MMP-2 secretion and activation.
Conversely, it has been shown in pancreatic cancer
cells that QSOX1 favored the activities but not the
secretion of MMP-2 and MMP-9; whereas, QSOX1, in
our breast cancer cell models, decreases both the activ-
ity and secretion of these MMPs. The discrepancies
between our results on breast cancer cells and Katch-
man’s results on pancreatic cells could be explained by
differential expression of QSOX1 isoforms and its sub-
strates availability. Furthermore, QSOX1 participates to
the redox state control together with a network of pro-
teins like PDI, Ero1, Gluthatione reductase or thioredox-
ins. It would be interesting to know the expression level
of all these actors to understand how QSOX1 could
generate opposite effects.
Given these conflicting results between the role of
QSOX1 in the breast and pancreas cancer cell models,
we performed an in vivo study. We demonstrated that
QSOX1 drastically inhibited tumor growth. Moreover, it
should be noted that during the tumor resection, we
observed that QSOX1 was unfavorable for tumor inva-
sion in subjacent muscle tissue. By inhibiting MMP-2,
an enzyme involved in tumor development, angiogenesis
and metastasis [42], QSOX1 could disfavor breast tumor
development and aggressiveness. Indeed, it has been
demonstrated in endothelial cancer cell models that
QSOX1 could inhibit angiogenesis [18]. It would conse-
quently also be interesting to study angiogenesis to bet-
ter understand the effect of QSOX1 on tumor growth
through MMP-2 activity regulation.
Conclusion
In our study, we demonstrate that QSOX1 could inhibit
breast tumor development and aggressiveness, which is
in agreement with our findings, indicating that a high
QSOX1 expression is associated with a better survival for
breast cancer patients. QSOX1 could be regarded as a
new marker of good prognosis. All our data provide new
insights into the role of QSOX1 in cancer cell biology.
Additional material
Additional file 1: Tumor localization during their excision. During
the excision of tumors (white arrow), tumors from the cell line MDA-MB-
231 shC developed just under the skin of animals while tumors from
MDA-MB-231 shQSOX1-1 developed in the subjacent muscle tissue.
Abbreviations
DMEM: Dulbecco’s Minimum Essential Medium; ECM: Extra Cellular Matrix;
ER: Estrogen Receptor; ERV/ALR: Essential for Respiration and Vegetative
growth/Augmenter of Liver Regeneration; FAD: Flavin Adenine Dinucleotide;
FCS: Fetal Calf Serum; GAPDH: GlycerAldehyde-3-Phosphate DeHydrogenase;
HRP: HorseRadish Peroxidase; HUVEC: Human Umbilical Vein Endothelial Cell;
IDC: Invasive Ductal Carcinomas; MCF-7: Michigan Cancer Foundation-7;
MDA-MB-231: M.D Anderson-Metastatic Breast-231; MDA-MB-453: M.D
Anderson-Metastatic Breast-453; MMP-2: Matrix MetalloProteinase-2; OA-Hy:
cis-9-OctAdecenoyl-N-Hydroxylamide; PAI-1: Plasminogen Activator Inhibitor-
1; PDI: Protein Disulfide Isomerase; PgR: Progesterone Receptor; PVDF:
PolyVinyllidene DiFluoride; QSOX1: Quiescin/Sulfhydryl OXidase 1; ROS:
Reactive Oxygen Species; RTqPCR: Reverse Transcription quantitative
Polymerisation Chain Reaction; SBR: Scarff, Bloom and Richardson; SDS:
Sodium DodecylSulfate; SDS PAGE: SDS PolyAcrylamide Gel Electrophoresis;
shRNA: Small Hairpin RNA; TIMP: Tissue Inhibitor of MetalloProteinases; TBST:
Tris Buffered Saline Tween
Acknowledgements
We are grateful to Jean Y Bobin (Centre Hospitalier Lyon Sud), J Datchary
(Centre Hospitalier Régional, Annecy) and G De Laroche (Clinique Mutualiste,
St Etienne) for providing breast cancer tumors and clinical data. We thank F.
Bonnefoy for CIEA NOG Mice breeding. We thank Pierre Y Rysold for his
valuable help during immunohistochemistry experiments. We thank J
Radom for the gift of coding sequence of QSOX1-S splice variant 2, I Idirene
for the gift of HT-1080 cells, F Poncet (Plateforme séquençage, IFR133,
Besançon), L Pagnot, V Perez and E Bedel for technical help and Nicole J Le
Grand for critical reading of the paper.
This work was supported by a grant from the “Ligue Nationale Contre le
Cancer” (Conférence de Coordination InterRégionale-Grand Est). N Pernodet
is supported by a fellowship from “Ville de Besançon”.
The clinical research work was supported by “Ligue Nationale Contre le
Cancer” (Drôme, Haute Savoie, Loire, Saône & Loire and Rhône committees).
Author details
1Université de Franche-Comté, EA3922 « Estrogènes, Expression Génique et
Pathologies du Système Nerveux Central », IFR133, U.F.R. Sciences et
Techniques, 16 route de Gray, 25030 Besançon Cedex, France. 2Université de
Bourgogne, EA7270, Equipe ‘Biochimie du Peroxysome, Inflammation et
Métabolisme Lipidique’ (Bio-peroxIL), 6 Bd Gabriel, 21000 Dijon, France.
3Service de Biochimie Biologie Moléculaire Sud, Centre Hospitalier Lyon sud,
Hospices Civils de Lyon, Pierre Bénite, France. 4Université de Franche Comté,
UMR INSERM-UFC-EFS 1098 « Relation Hôte Greffon et Ingénierie Cellulaire
et Génique », 240 route de Dôle, 25000 Besançon, France. 5Université
François Rabelais, INSERM U1100, 10 boulevard Tonnellé, 37000 Tours,
France.
Pernodet et al. Breast Cancer Research 2012, 14:R136
http://breast-cancer-research.com/content/14/5/R136
Page 13 of 15
Authors’ contributions
NP performed research, analyzed data and wrote the paper. FH performed
research and analyzed data. PA participated in data interpretation and in the
writing of the paper. AV participated in experiment design. FD performed
clinical data analysis and interpretation. MA performed clinical RT-qPCR
analysis. CB provided his expertise in in vivo cancer experiments. JRP
performed in vivo experiments execution. GV performed
immunohistochemistry data analysis and interpretation. FE provided critical
reagents. MJ participated in writing of the manuscript. GD designed
research, analyzed data and wrote the paper. All authors have read and
approved the manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 17 February 2012 Revised: 17 September 2012
Accepted: 24 October 2012 Published: 25 October 2012
References
1. Musard JF, Sallot M, Dulieu P, Fraichard A, Ordener C, Remy-Martin JP,
Jouvenot M, Adami P: Identification and expression of a new sulfhydryl
oxidase SOx-3 during the cell cycle and estrus cycle in uterine cells.
Biochem Biophys Res Commun 2001, 287:83-91.
2. Coppock DL, Cina-Poppe DA, Gilleran S: The quiescin Q6 gene (QSCN6) is
a fusion of two ancient gene families: thioredoxin and ERV1. Genomics
1998, 54:460-468.
3. Coppock DL, Kopman C, Gudas J, Cina-Poppe DA: Regulation of the
quiescence-induced genes: quiescin Q6, decorin and ribosomal protein
S29. Biochem Biophys Res Commun 2000, 269:604-610.
4. Benayoun B, Esnard-Fève A, Castella S, Courty Y, Esnard F: Rat seminal
vesicle FAD-dependent sulfhydryl oxidase. Biochemical characterization
and molecular cloning of a member of the new sulfhydryl oxidase/
quiescin Q6 gene family. J Biol Chem 2001, 276:13830-13837.
5. Tury A, Mairet-Coello G, Poncet F, Jacquemard C, Risold PY, Fellmann D,
Griffond B: QSOX sulfhydryl oxidase in rat adenohypophysis: localization
and regulation by estrogens. J Endocrinol 2004, 183:353-363.
6. Coppock DL, Thorpe C: Multidomain flavin-dependent sulfhydryl
oxidases. Antioxid Redox Signal 2006, 8:300-311.
7. Hoober KL, Joneja B, White HB, Thorpe C: A sulfhydryl oxidase from
chicken egg white. J Biol Chem 1996, 271:30510-30516.
8. Thorpe C, Hoober KL, Raje S, Glynn NM, Burnside J, Turi GK, Coppock DL:
Sulfhydryl oxidases: emerging catalysts of protein disulfide bond
formation in eukaryotes. Arch Biochem Biophys 2002, 405:1-12.
9. Hoober KL, Sheasley SL, Gilbert HF, Thorpe C: Sulfhydryl oxidase from egg
white. A facile catalyst for disulfide bond formation in proteins and
peptides. J Biol Chem 1999, 274:22147-150.
10. Thorpe C, Coppock DL: Generating disulfides in multicellular organisms:
emerging roles for a new flavoprotein family. J Biol Chem 2007,
282:13929-13933.
11. Morel C, Adami P, Musard JF, Duval D, Radom J, Jouvenot M: Involvement
of sulfhydryl oxidase QSOX1 in the protection of cells against oxidative
stress-induced apoptosis. Exp Cell Res 2007, 313:3971-3982.
12. Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM,
Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD: Antioxidant enzyme
expression and reactive oxygen species damage in prostatic
intraepithelial neoplasia and cancer. Cancer 2000, 89:123-134.
13. Oberley TD: Oxidative damage and cancer. Am J Pathol 2002, 160:403-408.
14. Coppock DL, Kopman C, Scandalis S, Gilleran S: Preferential gene
expression in quiescent human lung fibroblasts. Cell Growth Differ 1993,
4:483-493.
15. Antwi K, Hostetter G, Demeure MJ, Katchman BA, Decker GA, Ruiz Y,
Sielaff TD, Koep LJ, Lake DF: Analysis of the plasma peptidome from
pancreas cancer patients connects a peptide in plasma overexpression
of the parent protein in tumors. J Proteome Res 2009, 8:4722-4731.
16. Katchman BA, Antwi K, Hosteller GH, Demeure MJ, Watanabe A, Decker GA,
Miller LJ, Von Hoff DD, Lake DF: Quiescin sulfhydryl oxidase 1 promotes
invasion of pancreatic tumor cells mediated by matrix
metalloproteinases. Mol Cancer Res 2011, 9:1621-1631.
17. Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J: Loss of
Nkx3.1 leads to the activation of discrete downstream target genes
during prostate tumorigenesis. Oncogene 2009, 28:3307-3319.
18. Hellebrekers DM, Melotte V, Vire E, Langenkamp E, Molema G, Fuks F,
Herman JG, Van Criekinge W, Griffioen AW, van Engeland M: Identification
of epigenetically silenced genes in tumor endothelial cells. Cancer Res
2007, 67:4138-4148.
19. Berthier A, Seguin S, Sasco AJ, Bobin JY, De Laroche G, Datchary J, Saez S,
Rodriguez-Lafrasse C, Tolle F, Fraichard A, Boyer-Guittaut M, Jouvenot M,
Delage-Mourroux R, Descotes F: High expression of gabarapl1 is
associated with better outcome for patients with lymph node-positive
breast cancer. Brit J Cancer 2010, 102:1024-1031.
20. EORTC: Revision of the standards for the assessment of hormone
receptors in human breast cancer. Report of the Second E.O.R.T.C.
Workshop, held on 16-17 March, 1979, in The Netherlands Cancer
Institute. Eur J Cancer 1980, 16:1513-1515.
21. Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, André J,
Bobin JY: Plasminogen activator inhibitor type 1 is the most significant
of the usual tissue prognostic factors in node-negative breast ductal
adenocarcinoma independent of urokinase-type plasminogen activator.
Clin Breast Cancer 2008, 8:168-177.
22. Berton A, Rigot V, Huet E, Decarme M, Eeckhout Y, Patthy L, Godeau G,
Hornebeck W, Bellon G, Emonard H: Involvement of fibronectin type II
repeats in the efficient inhibition of gelatinases A and B by long-chain
unsaturated fatty acids. J Biol Chem 2001, 276:20458-20465.
23. Simian M, Hirai Y, Navre M, Werb Z, Lochter A, Bissell MJ: The interplay of
matrix metalloproteinases, morphogens and growth factors is necessary
for branching of mammary epithelial cells. Development 2001,
128:3117-3131.
24. Hamburger AW: The human tumor clonogenic assay as a model system
in cell biology. Int J Cell Cloning 1987, 5:89-107.
25. Colburn NH, Bruegge WF, Bates JR, Gray RH, Rossen JD, Kelsey WH,
Shimada T: Correlation of anchorage-independent growth with
tumorigenicity of chemically transformed mouse epidermal cells. Cancer
Res 1978, 38:624-634.
26. Fidler IJ: Understanding bone metastases: the key to the effective
treatment of prostate cancer. Clin Adv Hematol Oncol 2003, 1:278-279.
27. Simon N, Noel A, Foidart JM: Evaluation of in vitro reconstituted
basement membrane assay to assess the invasiveness of tumor cells.
Invasion Metastasis 1992, 12:156-167.
28. Deryugina EI, Luo GX, Reisfeld RA, Bourdon MA, Strongin A: Tumor cell
invasion through matrigel is regulated by activated matrix
metalloproteinase-2. Anticancer Res 1997, 17:3201-3210.
29. Stamenkovic I: Matrix metalloproteinases in tumor invasion and
metastasis. Semin Cancer Biol 2000, 10:415-433.
30. Nemos C, Delage-Mourroux R, Jouvenot M, Adami P: Onset of direct 17-β
estradiol effects on proliferation and c-fos expression during
oncogenesis of endometrial glandular epithelial cells. Exp Cell Res 2004,
296:109-122.
31. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N,
Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ,
Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F,
Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A
collection of breast cancer cell lines for the study of functionally distinct
cancer subtypes. Cancer Cell 2006, 10:515-527.
32. Franken NA, Rodermond HM, Stap J, Haveman J, Van Bree C: Clonogenic
assay of cells in vitro. Nat Protoc 2006, 1:2315-2319.
33. Yan B, Smith JW: A redox site involved in integrin activation. J Biol Chem
2000, 275:39964-39672.
34. Yan B, Smith JW: Mechanism of integrin activation by disulfide bond
reduction. Biochemistry 2001, 40:8861-8867.
35. Lahav J, Gofer-Dadosh N, Luboshitz J, Hess O, Shaklai M: Protein disulfide
isomerase mediates integrin-dependent adhesion. FEBS Lett 2000,
475:89-92.
36. Lahav J, Jurk K, Hess O, Barnes MJ, Farndale RW, Luboshitz J, Kehrel BE:
Sustained integrin ligation involves extracellular free sulfhydryls and
enzymatically catalyzed disulfide exchange. Blood 2002, 100:2472-2478.
37. Durand MK, Bødker JS, Christensen A, Dupont DM, Hansen M, Jensen JK,
Kjelgaard S, Mathiasen L, Pedersen KE, Skeldal S, Wind T, Andreasen PA:
Plasminogen activator inhibitor-I and tumour growth, invasion, and
metastasis. Thromb Haemost 2004, 9:438-449.
38. Strimpakos A, Saif MW, Syrigos KN: Pancreatic cancer: from molecular
pathogenesis to targeted therapy. Cancer Metastasis Rev 2008, 3:495-522.
Pernodet et al. Breast Cancer Research 2012, 14:R136
http://breast-cancer-research.com/content/14/5/R136
Page 14 of 15
39. Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R,
Shima TB, Torri J, Donahue S, Lippman ME: Association of increased
basement membrane invasiveness with absence of estrogen receptor
and expression of vimentin in human breast cancer cell lines. J Cell
Physiol 1992, 150:534-544.
40. Gialeli C, Theocharis AD, Karamanos NK: Roles of matrix
metalloproteinases in cancer progression and their pharmacological
targeting. FEBS J 2011, 278:16-27.
41. Kandasamy AD, Chow AK, Ali MA, Schulz R: Matrix metalloproteinase-2
and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res
2010, 85:413-423.
42. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a
moving target for therapeutic intervention. J Clin Invest 1999,
103:1237-1241.
doi:10.1186/bcr3341
Cite this article as: Pernodet et al.: High expression of QSOX1 reduces
tumorogenesis, and is associated with a better outcome for breast
cancer patients. Breast Cancer Research 2012 14:R136.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pernodet et al. Breast Cancer Research 2012, 14:R136
http://breast-cancer-research.com/content/14/5/R136
Page 15 of 15
